JUN 17, 2015 8:00 AM PDT

Real-Time Profiling of Tumor Heterogeneity in Metastatic Disease

Sponsored by: Epic Sciences, Epic Sciences
Speaker
  • VP of Translational Research, Epic Sciences
    Biography
      Mark Landers has 20 years of experience developing and commercializing molecular assays to drive translational and clinical research. In his current position as VP of Translational Research at Epic Sciences, he is leading the development of assay's to characterize CTC by genotype and phenotype at the single cell level. These assays can be utilized to develop clinical tests to drive patient care decisions. Prior to his tenure at Epic Sciences, Mark was Head of R&D at AltheaDx where he developed several companion assays for targeted therapies. He has also held several senior level scientist positions in the San Diego biotech community, at companies including LifeTechnologies, Ceregene and Vical.

    Abstract
    DATE: June 17th, 2015
    TIME: 8am Pacific time, 11am Eastern time

    Spatial heterogeneity of tumors has been identified within and between metastatic lesions and can be visualized with targeted PET imaging, biopsy IHC and microdissected-targeted NGS. Tissue biopsies can underestimate clonal and phenotypic differences between metastatic sites, and lack of single cell characterization can homogenize intra-tumoral heterogeneity. Additionally, acquired therapeutic resistance leads to temporal heterogeneity of tumors leading to the need for longitudinal tissue biopsies in some patients. Recently, large investments into liquid biopsies have employed the utilization of cfDNA to identify tumor mutations with known targets or are correlated with resistance to disease. However, utilization of cfDNA as a primary tool can underestimate intra-patient tumor heterogeneity and neglect the protein drivers of disease progression, including tyrosine kinase receptor amplification, loss of tumor suppressor function, epithelial plasticity. At Epic Sciences, we have developed a platform to characterize single circulating tumor cells (CTCs) for morphologic, protein and genomic targets at the single cell level and have applied the platform to thousands of samples from metastatic cancer patients. We will present data on the impact of morphology, protein chemistry and genomics of single CTCs in the context of contemporary unmet clinical needs in mCRPC. The impact of this clinical data suggests employment of a rational development of combination therapies to combat disease heterogeneity.

    Show Resources
    You May Also Like
    JAN 23, 2020 9:00 AM PST
    C.E. CREDITS
    JAN 23, 2020 9:00 AM PST
    DATE: January 23, 2020 TIME: 9:00am PST, 12:00pm EST...
    APR 07, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    APR 07, 2020 8:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: April 7, 2020 TIME: 8:00am PT, 11:00am ET This webinar sets out to establish why quality control is key to robust, reliable, reproducible science. We will look at best practice criteri...
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    C.E. CREDITS
    MAY 08, 2020 10:00 AM PDT
    Add to Calendar Select one of the following: iCal Google Calendar Outlook Calendar Yahoo Calendar
    DATE: May 8, 2020 TIME: 10:00am PT, 11:00am MT, 1:00pm ET The application of next generation sequencing to interrogate immune repertoires and methods in which these highly complex dataset...
    NOV 18, 2019 7:00 AM PST
    C.E. CREDITS
    NOV 18, 2019 7:00 AM PST
    DATE: November 18, 2019TIME: 7:00am PST, 11:00am EST, 4:00pm CEWT How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop th...
    FEB 26, 2020 9:00 AM PST
    C.E. CREDITS
    FEB 26, 2020 9:00 AM PST
    DATE: February 26, 2020 TIME: 9:00am PST 3D cell culture and analysis and the study of organoids and spheroids are becoming more prevalent as a research method in publications as traditional...
    MAR 31, 2020 9:00 AM PDT
    C.E. CREDITS
    MAR 31, 2020 9:00 AM PDT
    DATE: March 31, 2020 TIME: 9:00am PT, 12:00pm ET HER2-positive breast cancer is a type of breast cancer caused by over-expression of a protein called human epidermal growth factor receptor 2...
    Loading Comments...
    Show Resources